QIAGEN has received approval from the FDA for its second QIAstat-Dx mini gastrointestinal panel.
QIAGEN, based in Germantown, Maryland, and Venlo, Netherlands, has received approval from the U.S. Food and Drug Administration (FDA) for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, enhancing its range of syndromic tests in the U.S. This is the second FDA clearance for a QIAstat-Dx panel in 2025, following the authorization of five panels for the QIAstat-Dx system in the past ten months.
Qiagen N.V., a medical diagnostics company from the Netherlands, is experiencing market challenges because of recent worries about NIH funding, even though it has solid financial results and a wide range of products. In fiscal year 2024, the company's free cash flow saw significant improvement, and last month, it revealed a $300 million stock buyback plan. The following paragraphs will provide an analysis of Qiagen N.V.
QGEN's strong performance in the fourth quarter of 2024 is supported by a robust portfolio.
Qiagen N.V. (NYSE:QGEN) will hold its Q4 2024 Earnings Conference Call on February 6, 2025, at 10:00 AM ET. The call will feature company representatives including John Gilardi, Thierry Bernard, and Roland Sackers. Participants from various financial institutions, such as Jefferies, Bank of America Securities, and Citi, will also be present.
While the revenue and earnings per share (EPS) for Qiagen (QGEN) provide insight into its performance for the quarter ending December 2024, it could be helpful to look at how these important figures stack up against Wall Street predictions and last year's results.
Qiagen (QGEN) reported quarterly earnings of $0.61 per share, which is slightly below the Zacks Consensus Estimate of $0.62 per share. In comparison, the company earned $0.57 per share during the same period last year.
QGEN remains a focus for investors because of its strong growth in testing options and advantages from its strategic partnerships.
QIAGEN puts a lot of money into research and development to help its own growth, which includes adding new options to its main platforms.
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has revealed a new strategy to return around $300 million (up to EUR 281 million) to its shareholders. This will be done through a synthetic share repurchase that includes a direct capital repayment and a reverse stock split. This announcement follows a similar program in early 2024, which also returned about $300 million, totaling $600 million across both initiatives.